Avacta GroupLSE:AVCT +0.28%28 PB Ratio is 120.33 as of Jun. 24, 2026, which is 2158% above its 10-year median of 5.33. GuruFocus rates LSE:AVCT with a GF Score™ of 28/100 and a GF Value™ of £0.49 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,233 Biotechnology companies, Avacta Group ranks worse than 99.27% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-24), Avacta Group's share price is £0.722. Avacta Group's Book Value per Share for the quarter that ended in Dec. 2025 was £0.01. Hence, Avacta Group's PB Ratio of today is 120.33.
Warning Sign:
Avacta Group PLC stock PB Ratio (=121.67) is close to 10-year high of 121.67.
The historical rank and industry rank for Avacta Group's PB Ratio or its related term are showing as below:
LSE:AVCT'
s PB Ratio Range Over the Past 10 Years
Min: 0.52 Med: 5.33 Max: 121.67
Current: 120.33
During the past 13 years, Avacta Group's highest PB Ratio was 121.67. The lowest was 0.52. And the median was 5.33.
LSE:AVCT's PB Ratio is ranked worse than 99.27% of 1233
companies
in the Biotechnology industry
Industry Median: 2.83
vs LSE:AVCT: 120.33
During the past 12 months, Avacta Group's average Book Value Per Share Growth Rate was -76.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -57.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -50.30% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -33.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Avacta Group was 271.90% per year. The lowest was -57.80% per year. And the median was -9.95% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Avacta Group PB Ratio Related Terms
Avacta Group PB Ratio Historical Data
* Premium members only.
The historical data trend for Avacta Group's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Avacta Group's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avacta Group PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avacta Group's PB Ratio distribution charts can be found below:
* The bar in red indicates where Avacta Group's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Avacta Group's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Avacta Group (LSE:AVCT) has a PB Ratio of 120.33 as of Jun. 24, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Avacta Group and its competitors. This is 2158% above median its historical median of 5.33. Over the past decade, Avacta Group's PB Ratio has ranged from 0.52 to 121.67. According to the industry distribution chart, Avacta Group ranks #1224 out of 1233 companies in the Biotechnology industry, placing it in the top 99.3%.
Is Avacta Group's PB Ratio too high?
Avacta Group's current PB Ratio of 120.33 is 2158% above median its 10-year median of 5.33. Over the past 10 years, this metric has ranged from a low of 0.52 to a high of 121.67. The Biotechnology industry median PB Ratio is 2.83. Avacta Group's value of 120.33 is 4151.9% above this industry median. Based on the distribution chart, Avacta Group ranks #1224 out of 1233 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Avacta Group has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Avacta Group's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Avacta Group ranks #1224 out of 1233 companies for PB Ratio. This places Avacta Group in the lower half of its industry. The industry median PB Ratio is 2.83. Avacta Group's value of 120.33 is 4151.9% above this benchmark. Historically, Avacta Group's own PB Ratio has ranged from 0.52 to 121.67 over the past decade. While the company's 10-year median is 5.33 vs. the industry median of 2.83, Avacta Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.83, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avacta Group's current PB Ratio of 120.33 is 4151.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Avacta Group and its competitors. For the Biotechnology industry, the median PB Ratio is 2.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avacta Group's current PB Ratio is 120.33, which is 2158% above median its own 10-year median of 5.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avacta Group stock overvalued right now?
Based on GuruFocus' analysis, Avacta Group (LSE:AVCT) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.49, compared to a current price of £0.72 — trading 47.3% above its estimated fair value. The current PB Ratio is 120.33, which is 2158% above median its 10-year median of 5.33 and 4151.9% above the Biotechnology industry median of 2.83. Avacta Group's overall GF Score™ is 28/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Avacta Group (LSE:AVCT), the current PB Ratio is 120.33 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Avacta Group (LSE:AVCT) Overvalued in 2026?
Based on GuruFocus' analysis, Avacta Group stock appears to be overvalued.
The current stock price of £0.72 is trading 47.3% above its estimated GF Value™ of £0.49.
GuruFocus considers Avacta Group to be Significantly Overvalued.
Key valuation signals for LSE:AVCT:
PB Ratio: 120.33 (2158% above median its 10-year median of 5.33)
GF Value™: £0.49 vs. price of £0.72 (47.3% above fair value)
Industry Position: 4151.9% above the Biotechnology median (#1224 of 1233)
No single metric tells the full story. See the LSE:AVCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avacta Group PLC is a clinical-stage life sciences company expanding the reach of potent cancer therapies with the pre-CISION platform. pre-CISION is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate potent warheads in the tumor microenvironment while sparing normal tissues. The company's pipeline consists of pre-CISION peptide drug conjugates (PDC) or Affimer drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing benefits over traditional antibody drug conjugates. The firm has one reportable segment, Therapeutics, which is engaged in the development of novel cancer therapies harnessing its proprietary technology. Geographically, it derives revenue from South Korea.
28GF Score
Get the complete analysis for LSE:AVCT
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:AVCT has been successfully added to your 
